系统性红斑狼疮中的高密度脂蛋白:疾病生物标志物与潜在治疗策略
系统性红斑狼疮(SLE)患者动脉粥样硬化加速和心血管疾病(CVD)发生率增加,传统危险因素无法完全解释。HDL水平降低、组成和功能改变可能参与其中;SLE的炎症、氧化应激和自身免疫导致HDL形成促炎、功能障碍的HDL,后者可作为动脉粥样硬化加速的重要生物标志物,HDL靶向治疗(尤其输注重组HDL)可能是潜在干预策略。
要点
- SLE患者HDL水平降低且组成功能改变,形成促炎、功能障碍HDL。
- 功能障碍HDL抗动脉粥样硬化功能受损,可能促进动脉粥样硬化形成。
- 功能障碍HDL可作为SLE动脉粥样硬化加速的重要生物标志物。
核心结论
- SLE中功能障碍HDL可能作为动脉粥样硬化加速的重要生物标志物,HDL靶向治疗尤其是输注重组HDL可能成为SLE合并CVD患者的潜在治疗干预。
研究设计与样本
- 综述性文章,总结SLE中HDL水平、组成和功能改变及其与动脉粥样硬化和CVD的关系。
主要发现
- SLE患者HDL水平降低,HDL组成和功能改变,形成促炎、功能障碍HDL。
- SLE的全身炎症、氧化应激和自身免疫诱导HDL大小分布及蛋白质组和脂质组特征改变。
- 狼疮改变的HDL胆固醇流出能力降低、抗氧化能力受损、抗炎特性减弱。
- 功能障碍HDL可能通过诱导炎症促进动脉粥样硬化形成。
临床怎么用
- 功能障碍HDL可作为SLE患者动脉粥样硬化加速的生物标志物。
- HDL靶向治疗,尤其是输注重组HDL,可能是SLE合并CVD患者的潜在治疗干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic lupus erythematosus (SLE) patients exhibit accelerated development of atherosclerosis and increased incidents of cardiovascular disease (CVD) that cannot be explained by traditional risk factors alone. Accumulating evidence suggests that reduced levels of high-density lipoproteins (HDLs), along with altered HDL composition and function, may contribute to the accelerated atherosclerosis in SLE patients. Normally, HDLs play various atheroprotective roles through facilitating cholesterol efflux, inhibiting vascular inflammation, and scavenging oxidative species. However, systemic inflammation, oxidative stress, and autoimmunity in SLE patients induce changes in HDL size distribution and proteomic and lipidomic signatures. These compositional changes in HDLs result in the formation of proinflammatory, dysfunctional HDL. These lupus-altered HDLs have impaired antiatherogenic function with reduced cholesterol efflux capacities, impaired antioxidation abilities, and diminished antiinflammatory properties. In fact, dysfunctional HDL may promote atherogenesis by inducing inflammation. Thus, dysfunctional HDLs could be an important biomarker of accelerated atherosclerosis in lupus. Additionally, HDL-targeted therapies, especially infusion of reconstituted HDLs, may serve as a potential therapeutic intervention for SLE patients with CVD.
引用
- Kim SY, Yu M, Morin EE, et al. High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy. Arthritis Rheumatol. 2019. PMID: 31350818. doi:10.1002/art.41059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。